NCT04831320View on ClinicalTrials.gov

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma
Interventions
DRUG

nab-paclitaxel

Supplied by Celgene Corporation

DRUG

Nivolumab

Supplied by Bristol-Myers Squibb

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04831320 - Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | Biotech Hunter | Biotech Hunter